OT4B

Executive Summary

OT4B is a French biotech startup founded in 2017 by the Prader-Willi syndrome (PWS) patient community to develop oxytocin as the first disease-modifying treatment for PWS. The company builds on over a decade of academic research led by Professor Maithé Tauber at Toulouse University Hospital, which demonstrated that early oxytocin administration can improve key symptoms in neonates with PWS. Currently in the preclinical stage, OT4B is advancing a proprietary formulation of oxytocin designed for neonatal use, with the goal of intervening early to alter disease trajectory. The company's patient-centric approach and strong ties to the PWS community position it well for future development, though significant regulatory and financing hurdles remain. A successful Phase 1/2 trial would be a major milestone, potentially attracting partnerships or funding for later-stage studies.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical proof-of-concept study in PWS animal model65% success
• Q2 2027IND/CTA submission for Phase 1 trial40% success
• Q2 2026Strategic partnership or licensing deal for oxytocin program30% success